![]() |
Pradaxa® vs Warfarin...
November 1, 2014 - Featured , In the News / Politics By: Kevin Lin, PharmD Candidate c/o 2015 — The FDA recently completed an observational cohort study that compared Pradaxa® (dabigatran) to warfarin for rates of ischemic stroke, intracranial hemorrhage, major gastrointestinal bleed, myocardial infarction, and death. The study enrolled more than 134,000 patients, with 64% over the age of 65 and found a lower risk… |
![]() |
Pediatric Hypertension...
August 1, 2014 - Clinical , Featured By: Anthony Botte and Tyler Valente, PharmD Candidates c/o 2016 – Diseases which are prevalent within the pediatric population require distinct protocols for treatment accompanied by the utmost care and precision. Pediatric hypertension (HTN) is one disease state in particular that has come to the forefront of medical practice in the United States over the… |
![]() |
Brown-Bag Event...
May 1, 2014 - Events , Featured By: Hayeon Na, Co-Copy Editor (Content Focused) – On February 26th, 2014, pharmacists, clinical faculty, and pharmacy students from St. John’s University College of Pharmacy and Health Sciences gathered at the Freeport Memorial Library for a “Brown Bag,” one of the yearly calendar events at the public library. This event was conducted through the joint… |
![]() |
Dietary Supplements and Their Potential Dangers...
March 1, 2014 - Professional Advice / Opinions By: Fatema Elias, Staff Writer – With the New Year and everyone committing to their New Year resolutions, more and more patients are coming into the pharmacy asking for recommendations, particularly for weight loss dietary supplements. I hesitate to recommend an over-the-counter dietary supplement for weight loss. However, we as pharmacists and pharmacy students have… |
![]() |
Calcium Intake and Risk of Myocardial Infarction...
February 1, 2013 - Clinical , Featured By: Lila Ahmed, PharmD Candidate c/o 2013 – In the past, numerous research efforts have attempted to prove the benefits and risks of calcium and multivitamin supplements with little success. Most of the studies performed were inconclusive and did not provide us with significant data; while some studies have found that calcium is beneficial for… |
![]() |
FDA Approves Apixaban For Nonvalvular Atrial Fibrillati...
January 1, 2013 - Clinical , Featured , In the News / Politics By: Alexandra Alleva, PharmD candidate c/o 2013 – As of December 28th, Bristol-Myers Squibb and Pfizer’s brand name oral anticoagulant, Eliquis® (apixaban), attained FDA approval.1 This occurred one month after its approval in Europe and Canada, following longer than expected waits in the US due to further investigation requests by the FDA.2 The much-anticipated anticoagulant is… |
![]() |
Matching Challenge: Over-the-Counter Products...
August 1, 2012 - Puzzles By: Mohamed Dungersi, Associate Student Editor – Match the following herbal products with their correct description: A. This product has been used to treat liver disease, including hepatitis and cirrhosis. It has also been used as a protective agent after the liver was exposed to alcohol, acetaminophen, and carbon tetrachloride.B. This product is extracted from… |
![]() |
Matching Challenge: Over-the-Counter Products...
July 1, 2012 - Puzzles By Mohamed Dungersi, Associate Student Editor – Match the following herbal products with their natural source and reason for use: A. This product is a source of omega-3 fatty acids, primarily docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). It is used to lower triglyceride levels, to lower high blood pressure, and for a variety of… |
![]() |
Link Revealed: PPI Usage, Smoking and Bone Fractures...
February 1, 2012 - Clinical , In the News / Politics By: Ebey P. Soman – Proton pump inhibitors (PPIs) are medications commonly prescribed to treat heartburn, acid reflux disease, and ulcers. Almost a vast majority of patients in the United States seem to be taking a PPI, either as a prescription or from over-the-counter (OTC). Researchers recently discovered associations between the long-term use of PPIs… |
![]() |
Proton Pump Inhibitors and the Treatment of Osteoporosi...
February 1, 2012 - Clinical , Featured By: Neal Shah – Osteoporosis is a disease of the bone characterized by decreased bone mineral density (BMD), which reduces the ability of bone to provide adequate structural support. The main cause of this decreased BMD is inadequate calcium intake or absorption. The decreased BMD can cause diffuse lesions throughout the skeletal system and can… |